Registry of 919 Patients with Thrombotic Microangiopathies across Japan: Database of Nara Medical University during 1998-2008
スポンサーリンク
概要
- 論文の詳細を見る
Background Thrombotic microangiopathies (TMAs) are pathological conditions characterized by generalized microvascular occlusion by platelet thrombi, thrombocytopenia, and microangiopathic hemolytic anemia. Two typical phenotypes of TMAs are hemolytic-uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP). Severe deficiency of plasma ADAMTS13 activity (ADAMTS13: AC) is more specific for TTP, but not for HUS. Since 1998, our laboratory has functioned as a nationwide referral center for TMAs by analyzing ADAMTS13. Methods Of 1,564 patients tested from 426 hospitals, 919 were positive for TMA. Levels of ADAMTS13: AC and the ADAMTS13 neutralizing autoantibody (ADAMTS13: INH) were determined by chromogenic act-ELISA and/or by classic von Willebrand factor multimer assay. Results TMA patients consisted of two groups: severe (less than 3% of normal control) and non-severe deficiency of ADAMTS13: AC. Both groups were divided into congenital (n=65) and acquired (n=854) TMA. Of the former, 41 had congenital deficiency of ADAMTS13: AC, while the remaining 24 had disease of unknown etiology. The 854 patients with acquired TMA could be largely grouped into three categories: idiopathic TTP (n=284), idiopathic HUS (n=106), and secondary TMAs (n=464). The secondary TMAs were observed in heterogeneous patient groups and were associated with drugs, connective tissue diseases, malignancies, transplantation, pregnancy, E. coli O157: H7 infection, and other factors. All of the patients with acquired severe ADAMTS13: AC deficiency were positive for ADAMTS13: INH. Conclusion Although TMAs are highly heterogeneous pathological conditions, one-third of TMA patients have severe deficiency of ADAMTS13: AC. Platelet transfusions to such patients are contraindicated. Rapid ADAMTS13: AC assays are therefore prerequisite to appropriately treat TMA patients.
論文 | ランダム
- マラリア (新時代のワクチン戦略について考える) -- (期待されているこれからのワクチン)
- P-1-168 全結腸壊死を伴った大腸癌イレウスの1例(小腸・大腸 急性腹症1,一般演題(ポスター),第63回日本消化器外科学会総会)
- O-3-108 胆膵領域悪性腫瘍に対する膵切除後膵液瘻の予後に対する影響(胆・膵 PD再建8,一般演題(口演),第63回日本消化器外科学会総会)
- O-2-315 上部胃癌における脾門リンパ節転移状況と脾摘の意義についての検討(胃 転移,一般演題(口演),第63回日本消化器外科学会総会)
- RS-369 当科における下部直腸癌に対する側方郭清の適応と治療成績(要望演題24 下部直腸癌に対する側方郭清の適応と治療成績,第63回日本消化器外科学会総会)